World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
39121
World Ranking
10752
National Ranking
5530

Eric Raymond publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eric Raymond sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 591 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eric Raymond D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eric Raymond sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eric Raymond is affiliated with St. Joseph Hospital in the United States and has contributed extensively to research within medicine and molecular biology, particularly focused on oncology and related biomedical fields.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Key subfields of their research encompass:

  • Oncology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Epidemiology
  • Cancer Research

The primary topics covered in their work reflect a focus on cancer biology and treatment modalities:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Autophagy in Disease and Therapy
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer, Hypoxia, and Metabolism
  • Cancer Immunotherapy and Biomarkers
  • Neuroendocrine Tumor Research Advances

Eric Raymond has published repeatedly in several scientific journals, with frequent contributions to the following publication venues:

  • Targeted Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • PLoS ONE
  • European Journal of Cancer

Coauthor collaborations feature several individuals with multiple joint publications, including:

  • Sandrine Faivre
  • Annemilaï Tijeras-Raballand
  • Philippe Halfon
  • Valérie Paradis
  • Eloïne Bestion

Among recent publications, notable works include:

  • "Impact of the COVID-19 Outbreak on the Management of Patients with Cancer," 2020, Targeted Oncology
  • "GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions," 2021, Autophagy
  • "Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib," 2020, PLoS ONE
  • "Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression," 2021, British Journal of Cancer
  • "PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma," 2020, OncoImmunology

Best Publications

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

    Sandrine Faivre;Catherine Delbaldo;Karina Vera;Caroline Robert

  • Current development of mTOR inhibitors as anticancer agents.

    Sandrine Faivre;Guido Kroemer;Eric Raymond

  • Molecular basis for sunitinib efficacy and future clinical development

    Sandrine Faivre;George Demetri;William Sargent;Eric Raymond

  • mTOR-targeted therapy of cancer with rapamycin derivatives

    S. Vignot;S. Faivre;D. Aguirre;E. Raymond

  • Oxaliplatin: A review of preclinical and clinical studies

    E. Raymond;S. G. Chaney;A. Taamma;E. Cvitkovic

  • Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    Ann Lii Cheng;Yoon Koo Kang;Deng Yn Lin;Joong Won Park

  • Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

    Martyn E. Caplin;E. Baudin;P. Ferolla;P. Filosso

  • Oxaliplatin: mechanism of action and antineoplastic activity.

    E Raymond;S Faivre;J M Woynarowski;S G Chaney

  • Cellular and molecular pharmacology of oxaliplatin.

    Eric Raymond;Sandrine Faivre;Stephen Chaney;Jan Woynarowski

  • Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

    Eric Raymond;Jérôme Alexandre;Sandrine Faivre;Karina Vera

  • ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

    R. Garcia-Carbonero;H. Sorbye;E. Baudin;E. Raymond

  • Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.

    Eric Raymond;Sandrine Faivre;Jean Pierre Armand

  • Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

    Anne O'Donnell;Sandrine Faivre;Howard A. Burris;Daniel Rea

  • Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

    A. de Gramont;J. Vignoud;C. Tournigand;C. Louvet

  • Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.

    E Izbicka;R T Wheelhouse;R T Wheelhouse;E Raymond;K K Davidson

  • Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.

    Laurent Meijer;Eric Raymond

  • Oxaliplatin-induced damage of cellular DNA.

    Jan M. Woynarowski;Sandrine Faivre;Sandrine Faivre;Maryanne C.S. Herzig;Brenda Arnett

  • New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

    Sandrine Faivre;Siham Djelloul;Eric Raymond

  • Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

    Sandrine Faivre;Eric Raymond;Eveline Boucher;Jean Douillard

Frequent Co-Authors

Pascal Hammel
Pascal Hammel University of Paris-Saclay
Valérie Paradis
Valérie Paradis Université Paris Cité
Ivan Bièche
Ivan Bièche Institute Curie
Philippe Ruszniewski
Philippe Ruszniewski Université Paris Cité
Anne Couvelard
Anne Couvelard Université Paris Cité
Juan W. Valle
Juan W. Valle University of Manchester
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)
Jacques Belghiti
Jacques Belghiti Beaujon Hospital
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Michel Vidaud
Michel Vidaud Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The field of medicine offers diverse pathways beyond traditional medical school, many of which are accessible through flexible online degree programs. For those seeking a doctoral route, online pharmacist programs provide a pathway to a pharmacy career while allowing you to study remotely.

Aspiring professionals interested in healthcare technology and management might consider a him associate degree online, which can open doors to roles in health information management. This field is growing rapidly, offering strong job prospects and the ability to make a meaningful impact on healthcare systems.

If you are looking for entry into the healthcare field quickly, medical billing and coding classes online can prepare you for essential roles in hospitals, clinics, and insurance companies without the need for a multi-year degree.

For those pursuing advanced clinical practice, completing training through the cheapest np school options can help you become a nurse practitioner. This route offers both flexibility and significant responsibility in patient care.

Best Scientists Citing Eric Raymond

Trending Scientists

Recently Published Articles